Zevra Therapeutics Inc (NASDAQ: ZVRA) kicked off on Friday, up 3.52% from the previous trading day, before settling in for the closing price of $7.39. Over the past 52 weeks, ZVRA has traded in a range of $3.89-$8.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 44.97% over the last five years. While this was happening, its average annual earnings per share was recorded -22.00%. With a float of $52.20 million, this company’s outstanding shares have now reached $52.62 million.
The firm has a total of 69 workers. Let’s measure their productivity. In terms of profitability, gross margin is 46.32%, operating margin of -309.83%, and the pretax margin is -273.36%.
Zevra Therapeutics Inc (ZVRA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Zevra Therapeutics Inc is 0.79%, while institutional ownership is 30.55%. The most recent insider transaction that took place on Jul 17 ’24, was worth 13,540. In this transaction CFO & Treasurer of this company bought 2,000 shares at a rate of $6.77, taking the stock ownership to the 18,469 shares. Before that another transaction happened on Jul 16 ’24, when Company’s Director bought 10,000 for $6.81, making the entire transaction worth $68,065. This insider now owns 20,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -22.00% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Take a look at Zevra Therapeutics Inc’s (ZVRA) current performance indicators. Last quarter, stock had a quick ratio of 2.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.68, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Analysing the last 5-days average volume posted by the [Zevra Therapeutics Inc, ZVRA], we can find that recorded value of 0.4 million was lower than the volume posted last year of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 75.13%. Additionally, its Average True Range was 0.48.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 81.37%, which indicates a significant decrease from 95.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.44% in the past 14 days, which was lower than the 75.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.19, while its 200-day Moving Average is $5.56. Now, the first resistance to watch is $7.80. This is followed by the second major resistance level at $7.95. The third major resistance level sits at $8.20. If the price goes on to break the first support level at $7.39, it is likely to go to the next support level at $7.14. Should the price break the second support level, the third support level stands at $6.99.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
The company with the Market Capitalisation of 402.54 million has total of 41,853K Shares Outstanding. Its annual sales at the moment are 27,460 K in contrast with the sum of -46,050 K annual income. Company’s last quarter sales were recorded 4,450 K and last quarter income was -19,930 K.
